PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17500623-2	2007	DESIGN: Three hundred twenty-three participants in a bupropion SR smoking cessation effectiveness trial with 12-month follow-up were genotyped for variants of dopamine receptor gene DRD2 and dopamine transporter SLC6A3.	Bupropion	53-62	dopamine receptor D2	Homo sapiens	182-186	
17654295-8	2007	Although these results require replication, the data suggest preliminarily that the DRD2-Taq1A polymorphism may influence treatment response to bupropion for smoking cessation and, further, that exploration of gene x gene and gene x craving interactions in future, larger studies may provide mechanistic insights into the complex pharmacodynamics of bupropion.	Bupropion	144-153	dopamine receptor D2	Homo sapiens	84-88	
18058343-0	2007	Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.	Bupropion	0-9	dopamine receptor D2	Homo sapiens	62-66	
18058343-6	2007	These data suggest that bupropion may be effective for smoking cessation only in a subgroup of smokers with the DRD2 Taq1 A2/A2 genotype.	Bupropion	24-33	dopamine receptor D2	Homo sapiens	112-116	
15138759-5	2004	RESULTS: Carriers of the DRD2 A1 minor allele exhibited significant increases in the rewarding value of food following abstinence from smoking, and these effects were attenuated by bupropion treatment ( P=0.03 for medication by genotype interaction).	Bupropion	181-190	dopamine receptor D2	Homo sapiens	25-29	
15492764-0	2005	Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.	Bupropion	87-99	dopamine receptor D2	Homo sapiens	18-22	
15492764-2	2005	In a study of smokers enrolled in an open-label, randomized effectiveness trial, we investigated whether variants in the DRD2 receptor gene are associated with smoking cessation outcomes following treatment with a combination of bupropion SR and behavioral counseling.	Bupropion	229-241	dopamine receptor D2	Homo sapiens	121-125	
12474115-12	2002	CONCLUSIONS: These findings suggest that bupropion"s effect on REM latency and its AD action might be linked, possibly via dopamine (D(2)) receptor-mediated effects, or by noradrenergic mechanism(s).	Bupropion	41-50	dopamine receptor D2	Homo sapiens	123-147	
14668077-0	2003	Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?	Bupropion	66-89	dopamine receptor D2	Homo sapiens	9-13	
14668077-5	2003	Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that craving, irritability, and anxiety were significantly attenuated only among subjects with DRD2-Taq1 A2/A2 genotypes.	Bupropion	11-20	dopamine receptor D2	Homo sapiens	186-190	
14668077-7	2003	These data suggest that bupropion attenuates specific symptoms of the nicotine withdrawal syndrome and that this effect may be modified by genotype for the dopamine D2 receptor.	Bupropion	24-33	dopamine receptor D2	Homo sapiens	156-176	
33236485-0	2021	Weight Loss Response to Naltrexone/Bupropion is Modulated by the Taq1A Genetic Variant near DRD2 (rs1800497): A Pilot Study.	Bupropion	35-44	dopamine receptor D2	Homo sapiens	92-96